Biotechnology Value Fund

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 45
Average round size
info
The average size of a deal this fund participated in
$65M
Portfolio companies 39
Rounds per year 1.55
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.13
Exits 30
Key employees 5
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Biotechnology Value Fund is the famous VC, which was founded in 1993. The venture was found in North America in United States. The leading representative office of defined VC is situated in the San Francisco.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Biotechnology Value Fund, startups are often financed by Third Rock Ventures, The Column Group, Celgene. The meaningful sponsors for the fund in investment in the same round are EcoR1 Capital, RA Capital Management, Nextech Invest. In the next rounds fund is usually obtained by EcoR1 Capital, Surveyor Capital, RA Capital Management.

We also calculated 5 valuable employees in our database.

Among the most successful fund investment fields, there are Health Care, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Relay Therapeutics, Merus, Vividion Therapeutics

Comparing to the other companies, this Biotechnology Value Fund performs on 30 percentage points more the average number of lead investments. The high activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The real fund results show that this VC is 11 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Biotechnology Value Fund:
Typical Co-investors
Biotechnology Value Fund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Biotechnology Value Fund:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nimbus Therapeutics

Alternative Medicine
Biotechnology
Health Care
Therapeutics
$105M13 Jul 2021 Cambridge, Massachusetts, United States

Biotechnology
Life Science
$100M08 Apr 2021 Massachusetts, United States

Pyxis Oncology

Biotechnology
Health Care
Pharmaceutical
$152M30 Mar 2021 Boston, Massachusetts, United States

Gritstone Oncology

Biotechnology
Health Care
Therapeutics
$125M28 Dec 2020 California, United States

Olema Oncology

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$54M22 Jul 2020 San Francisco, California, United States

Autobahn Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$76M11 Jun 2020 San Diego, California, United States

Surface Oncology

Biotechnology
Health Care
Life Science
$28M20 May 2020 Cambridge, Massachusetts, United States

Kymera Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$102M12 Mar 2020 Cambridge, Massachusetts, United States

Syndax Pharmaceuticals

Biotechnology
Clinical Trials
Drug Discovery
Pharmaceutical
$30M31 Jan 2020 Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Biotechnology Value Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: